ArticleCancer research and treatment2024

Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea.

Ji Yun Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.